Abstract
We have developed a prolonged release preparation of adriamycin with silicon as a carrier for use in localized chemotherapy of recurrent and metastatic cancer and in embolism chemotherapy of primary cancer. In the present study, we observed the temperature sensitivity of the drug release and tissue degeneration due to embedding in the muscle and tumor tissue in this system, and investigated the antitumor effects using cancer bearing rats, The results indicated that the drug release increased about two-fold when the temperature was changed from 37 to 43°C, and there was a marked improvement in component drug release efficiency when glycine was added in place of the silicon. When the prolonged-release preparation of adriamycin was embedded in the muscle tissue, degeneration of the surrounding tissue increased with the increase in the dose of the drug, There was also tissue degeneration associated with necrosis in the rapidly growing tumor tissue, and the drug showed continuous action. In the experiment using tumor-bearing rats, all of the tumors died within 10 days with an average survival period of 8.5±1.3 days after bearing the cancer in the control group, and an average survival period of at least 46.8 days, with 40% surviving for 60 days, in the group given the timerelease preparation. The prolonged release preparation showd marked life extending effects.
